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About Metabolon 
• Initial funding in 2003, raised $45 million to date 
• Sevin Rosen, Harris & Harris, Syngenta Ventures, Aurora Funds, 
Fletcher Spaght, Fulcrum Financial, Keating Capital Inc. 
• +60 million in bookings to date 
• +100 staff (40 PhDs) in Research Triangle Park, NC 
• Transformational technology marries software, know-
how and biochemical biomarker discovery  
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 Advancing the field of metabolomics by pioneering 
and patenting the industry‟s leading biochemical 
biomarker discovery and profiling platform 
Company Key Points 
• Validated, pioneering technology poised to transform 
disease treatment and diagnosis 
• Strong IP protection with more than 100 patents filed, 17 issued 
• Profitable Metabalytics™ division growing rapidly with 
high repeat business from a Who‟s Who of pharma 
and biotech 
• Ex-U.S. expansion provides further growth opportunity 
• Technology and know-how also being applied to 
rapidly develop a robust diagnostics pipeline 
• Products help prevent disease with significant long-term costs, or 
affect patient management 
• Targeting 2 largest markets: type 2 diabetes and oncology 
• +50 peer-reviewed scientific papers published in the 
last 3 years. 
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Two Commercialization Paths 
 
Biomarker Discovery 
•mVision 
•mView 
•mSelect 
 
Biomarker Monitoring 
•mFocus 
•Quantose IR 
 
BioProcessMonitoring 
•COP  
 
 
 
 
 
 
 
 
Pharma, Biotech,  
Nutrition, Agri, 
University, Org 
 
 
2010 $14 Million 
2011 $20 Million 
Long-Term  
Value Creation 
 
Pipeline 
•Quantose 
•Prostarix DRE 
•Prostarix 
•Bladder cancer 
aggression 
•RCC aggression 
 
Patient Monitoring 
•Cisplatin 
 
 
 
 
 
 
 
Physicians and  
Patients 
NAD+
NADH
ATP
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Focus on Metabolism 
Disease 
Mechanism 
DNA 
RNA 
Proteins 
Metabolism 
Biochemistry Advantages 
Any sample type 
Many applications 
Fewer total biochemicals  
 
Solutions through 
Understanding 
Metabolism 
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Global Effects on 
Metabolism 
 
Disease Biomarkers 
Mechanistic Toxicology 
Drug MOA 
Cellular Characteristics 
  
Data 
Interpretation 
• 100‟s of Studies 
•Institutional Knowledge 
•Expert Biochemists 
Heat Maps by Pathway 
Metabolon Platform Technology 
Statistical Analysis 
                      
Metabolyzer™ 
Peak Detection 
Peak Integration 
Library Search 
RT, Mass, MS/MS 
QA/QC 
                      
Biochemical 
Extraction 
      UHPLC-MS/MS (+ESI) 
           GC-MS (+EI) 
      UHPLC-MS/MS (-ESI) 15,000 ion features 
15,000 ion features 
15,000 ion features 
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Intellectual Property 
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• Methods - Fundamental IP provided by pioneering patents, first filed in 2000 
• „Stepping Stone‟ Patents - Data analysis and analytical platform inventions 
• Growing Biomarker Patent Portfolio: 
    Issued and Pending patents for biomarkers of toxicity and diseases including: 
         Cancer, Insulin Resistance, Liver disease and Liver toxicity   
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Metabolytics Business 
Significant Customer Growth 
$60MM Cumulative Bookings  
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Metabolytics Business 
Financial Growth 
45% 
CAGR 
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Who‟s Who Customer Base 
 
 
Biomarker 
Discovery 
•mVision 
•mView 
•mSelect 
 
Biomarker 
Monitoring 
•mFocus 
•Quantose IR 
 
BioProcess 
•COP  
 
 
 
 
 
 
 
 
Pharma, Biotech,  
Nutrition, Agri 
University, Org 
Metabolon 
Diagnostics Division 
Diagnostics Business Strategy 
 
• Quantose™ insulin resistance test 
developed through commercial 
partnering and targeted business 
segments 
 
• Develop a fully integrated diagnostics 
business utilizing our understanding of 
cancer metabolism 
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Current Glycemic Diagnostics Do Not 
Measure IR 
Disease Progression 
Normal 
 Pre-Diabetic 
Diabetic 
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T2D patient with 
disease 5-7 yrs 
on average when 
first diagnosed. 
 
Pre-Diabetic 
T2D / 
 CVD Complications Normal 
Insulin Production 
In
su
lin
 R
es
is
ta
n
ce
/P
ro
d
u
ct
io
n
 
-cell Function  -  Diminishing 
Vascular Damage  - Increasing 
100 mg/dl 
125 mg/dl 
          NGT-IS        NGT-IR     IGT            T2D 
Insulin Resistance Diagnostic Test 
Diagnostic  
Testing 
FPG, OGTT, A1C 
Early 
Stage IR 
Middle 
Stage IR 
Late 
Stage IR 
Insulin Resistance 
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Quantose Market Opportunity 
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33% of the population in the developed world considered “at risk” 
 
Quantose peak royalty revenue potential ~$300M if one third of at risk patients 
get tested annually in the US alone 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Test Results 
 
 
PATIENT INFORMATION 
 
PHYSICIAN INFORMATION 
 
Date: 09/16/2010                          Ethnicity: Caucasian 
Name: John C. Smith                        Age: 49 
DOB: 11/4/1960                             Sex: Male   
Patient ID: 123-45-6789                Weight: 215 lb 
Patient address: Height:  
                                                                    BMI: 28.8 kg/m2 
                                                             Family History T2DM: Yes 
 
Physician Name Physician 
Address PCP Phone Number 
PCP Fax 
 
SPECIMEN DESCRIPTION 
 
Fasted EDTA plasma 
 
ASSAY DESCRIPTION 
 
  Quantose IR is a fasting blood test for insulin resistance (IR) that is based on a panel of markers. Insulin resistance is a condition in which the  
natural hormone  insulin becomes less effective at lowering blood sugars. Specifically, the cells that use insulin become less sensitive to insulin’s  
effects (low insulin sensitivity or high IR). Insulin Resistance is a recognized risk factor and predictor of type II diabetes and cardiovascular disease.  
The test results give a probability IR score to aid a physician in identifying high-risk, dysmetabolic IR patients earlier to more effectively prevent or  
delay metabolic disease progression related to IR.  The bottom tertile of insulin sensitivity in a general non-diabetic population is < 5.6 
mg/kg/min rate of glucose metabolism, whereas the upper 40% of insulin sensitivity (normal range) is > 7.5 mg/kg/min. 
 
RESULTS 
 
Normal Intermediate IR 
 
 
 SENSITIVIT 
  INSULIN SENSITIVITY                     
 
     High Intermediate          Low 
   
Diagnostic History 
 
Date 
 
M value* 
 
IR 
Probability 
 
 
FPG 
(mg/dL) 
 
 
BMI 
(kg/m
2
) 
 
8/12/2009 
 
6.3 
 
     45% 
 
94 
 
26.9 
 
12/02/2010 
 
5.1 
 
     61% 
 
98 
 
27.6 
 
05/01/2011 
 
4.5 
 
       89% 
 
95 
 
28.8 
   
CURRENT IR PROBABILITY SCORE:  81% 
 
Predicted M Value (Glucose Uptake Rate): 4.51 mg/kg/min 
Prediction Confidence Intervals: 4.12 – 5.14 mg/kg/min 
Predicted Diabetes Risk Assessment Score:  XX% p r e d i c t e d  risk of diabetes progression in 5 years 
 
TEST RESULTS SUMMARY 
 
IR probability > XX%; classified as highly insulin resistant (i.e. below  bottom quartile of insulin sensitivity in a general non -di abe t ic  population) 
 
ANALYTE 
 
CONCENTRATION 
 
ODDS  RATIOS FOR DISEASE RISK*                                                                 
AHB 
(Alpha-hydroxybutyrate) 
6.8   µg/ml 
Insulin sensitive  <3.8 µg/ml 
Intermediate  3.8–5 µg/ml 
Insulin resistant  >5.0   µg/ml 
 
L-GPC 
(Linoleoyl-glycerophosphocholine) 
12.7  µg/ml 
Insulin sensitive  >16.8  µg/ml 
Intermediate  13–16.8 µg/ml 
Insulin resistant   <13       µg/ml 
 
 
Oleic Acid 
103.2  µg/ml 
Insulin sensitive      < 73.5     µg/ml 
Intermediate 73.5-92.0 µg/ml 
Insulin resistant        > 92.0     µg/ml 
 
Lit. Ref.: Gall et al. PLoS One May 28; 5(5):e10883 (2010). *Data on file including odds ratios and predictiveness of T2D progression. 
 
Approved by:    Date:     
 
Metabolon, Inc. • 617 Davis Drive, Suite 400 • Durham, NC  27713 • Phone:  919.572.1711 • Fax: 919.572.1721 
  CLIA ID: 34D2017656           Form XXXX-XX 
Quantose: Intended Use  
Fasting plasma test to determine the risk of diabetes in 5 years 
 
 Monitors biomarkers for insulin 
resistance discovered and validated  
in  collaboration with top internationally  
recognized KOL‟s 
 
Earliest indication of Type 2 diabetes 
 
Measures the current status of IR and how that  
affects diabetes risk.  
 
Monitors health improvements from life style 
and drug interventions . 
 
Targets “at risk” patients with BMI of 26 to 32 
  
5% of patients monitoring their risk with  
Quantose improve their condition through  
more aggressive intervention 
 
More effective than any other measure in  
changing patient outcome 
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Cancer Diagnostics Business Strategy 
 
 
• Develop a fully integrated diagnostics business 
utilizing our understanding of cancer metabolism 
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• Tests focus on treatment management of cancer patients 
• Target significant underserved medical needs 
• Reduce healthcare costs while improving patient care 
• Build internal salesforce to call on urologists/oncologists 
• Run tests through CLIA laboratory to ensure quality, 
capture economics, build customer relationships 
Science of Cancer Investigation 
Warburg made a striking discovery in the 1920s that, even in 
the presence of ample oxygen, cancer cells prefer to 
metabolize glucose through non-oxidative pathways (aerobic 
glycolysis) – Warburg effect 
This insight has yielded seminal practical applications such as 
FDG PET for tumor  imaging 
However, for many years, Warburg effect largely viewed as  a 
reflection of a function of the hypoxic tumor environment 
Research continued but was eventually eclipsed by a captivating 
finding from a parallel track of cancer investigation ………… 
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Molecular Biology Explosion Eclipses 
Metabolic Inquiry 
• Upon the discovery of oncogenes, the molecular biology explosion 
surpassed Warburg’s line of inquiry for all but a small group of 
investigators 
• Eventually, a realization that Warburg’s findings and cancer activating 
mutations were intimately connected  
Peyton Rous isolated the 
first oncovirus 
(avian sarcoma virus) 
Bishop  & Varmus discovered that the 
these oncoviral genes were actually 
mutated host genes – “Oncogenes” 
1916          1977 
Kim & Dang. HIF-1-mediated expression of 
PDK: a metabolic switch required for cellular 
adaptation to hypoxia. Cell Metabolism, 
3:177-185 (2006)  
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Warburg Effect 
fructose 6-P 
glucose 6-P 
fructose 1,6-bisP 
DHAP 
1,3-bisphosphoglycerate 
glyceraldehyde-3-P 
3-phosphoglycerate 
2-phosphoglycerate 
phosphoenolpyruvate 
pyruvate 
glucose 
lactate 
TCA 
X 
12 metabolites 
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IDH1 mutation
glycogen
oligosaccharides
glucoseglucose-6-P
fructose-6-P
fructose-1,6 BP
glyceraldehyde-3-P
1,3-diphosphoglyderate
3-phosphoglyderate
2-phosphoglyderate
phosphoenolpyruvate
pyruvate lactate
acetyl-CoA
mannose-6-P
mannose
sorbitol
fructose
glucosamine-6-P
DHAP glycerol-3-P DAG
fructose-1-P
TAG
mannitol
ribulose 5-P
ribose 5-P
sedoheptulose 7-P
xylulose 5-Pribose
ribulose
6-phosphogluconate
glyceraldehyde
glyceraldehyde-3-P
fructose-6-Perythrose 4-P
xylulose 5-P glyceraldehyde-3-P
xylulose
glutamate
citrate
isocitrate
α-ketoglutarate
succinate
fumarate
malate
oxaloacetate
fatty acids 
(de novo biosynthesis)
citrate acetyl-CoA
succinyl-CoA
2-hydroxyglutarate
carnitine
acyl-CoA
acyl-carnitine
acyl-carnitine
acyl-CoA carnitine
3-hydroxybutyrate
DAG
fatty acids 
MAG
glycerol
CDP-choline
membrane lipid
phosphocholine 
ethanolamine
choline 
phosphoethanolamine
nucleotide biosynthesis
CDP-ethanolamine
isoleucine
2-methybutyryl-CoA
tiglyl-CoA
succinyl-CoA
3-methyl-2-oxovalerate
2-methyl-3-hydroxybutyryl-CoA
2-methylacetoacetyl-CoA
propionyl-CoA
methylmalonyl-CoA
methylmalonate semialdehyde
leucine
4-methyl-2-oxopentanoate
isovaleryl-CoA
3-methylcrotonyl-CoA
acetyl-CoA
3-methylglutaconyl-CoA
3-hydroxy-3-methylcrotonyl-CoA
valine
3-methyl-2-oxobutyrate
isobutyryl-CoA
methylacylyl-CoA
3-hydroxy-isobutyryl-CoA
3-hydroxyisobutyrate
succinyl-CoA
propionyl-CoA
methylmalonyl-CoA
BCAA 
carnitines
GSSG
betainedimethylglycinesarcosineglycine
tetrahydrofolate methyltetrahydrofolate
S-adenosylmethionine homocystheine
methylation reactions
(DNA, RNA, histones, lipids, …)
tryptophan kynurenine quinolinate
NAD+
nicotinamide (NAM)nicotinate mononucleotide (NAMN)
nicotinate adenine dinucleotide (NAAD) nicotinamide mononucleotide (NMN) 
nicotinate (NA)
nicotinamide riboside (NR)
NADPH production reactions
NADPH consumption reactions
NADH production reactions
NADH consumption reactions
FADH production reactions
FADH consumption reactions
ATP production reactions
ATP consumption reactions
isocitrate
α-ketoglutarate
acetyl-CoA
oxidized FAs
glutamine
UDP-GlcNAcglycosylation
amino acid (AA)
amino acid (AA)
α-ketobutyrate
2-aminobutyrate
ophthalmate
γ-glutamyl-
2-aminobutyrate
glycine
cys-gly
cysteine
γ-glutamylcysteine
GSH
glutamate
creatine
guanidinoacetate
methionine
S-adenosylmethionine
S-adenosylhomocysteine
homocysteine
cystathionine
γ-glutamyl-AA
5-oxoproline
Prostate Cancer
Diagnostics Product Pipeline 
Diagnostic 
Product 
Indication / Estimated 
Annual Market Size 
Business 
Case 
Feasibility Validation CLIA Ready Market 
Ready* 
Prostarix™DRE 
Guide prostate biopsy 
decision / $600 mil. 
Prostarix 
Prostate cancer aggression 
/ $619 mil. 
Vasicar™ 
Bladder cancer aggression 
/ $168 mil. 
Cisplatin toxicity 
Cisplatin treatment 
tolerance / $200 mil. 
Renal Cell 
Carcinoma 
aggressiveness 
Kidney cancer aggression/ 
$70 mil. 
2012 
2012 
2013 
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* Commercial launch is pending financing 
2013 
2013 
Company Summary 
• Validated, pioneering, patented technology 
poised to transform disease treatment and 
diagnosis 
• Over the past 5 years, rapidly growing 
metabolytics business.    320 studies completed in 
2010 processing over 33,000 samples.  +60m in 
bookings since inception. 
• Technology and know-how applied to develop a 
robust diagnostics pipeline targeting the largest 
healthcare disease categories. 
• Large scale biology studies (clinical, GWAS) 
started in 2009. 
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Metabolon GWAS Study  
Nature 477, Pages: 54–60 Sep 1st, 2011 
Study Rationale: 
Using Metabolon‟s Global 
Metabolomics to Phenotype 
Two Large Genomic Studies 
Global Metabolomics 
Platform 
556 Blood Biochemicals 
Measured 
Metabotype 
Genotype Phenotype 
cardio vascular 
diseases 
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• KORA Genomic Study 
• 1,768 individuals 
• 655,658 autosomal SNPs  
• TwinsUK: (Merlin) Genomic 
Study 
• 1056 individuals 
• 534,665 autosomal SNPs  
28 genomewide significant associations to 
biochemicals (p<2x10-12) in the discovery 
study 
-> 27 fully replicated in second study 
(p<2x10-5) 
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